Overview of Dr. Rubinstein
Dr. Maria Rubinstein is an oncologist in Basking Ridge, NJ and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Northeast Ohio Medical University and has been in practice 4 years. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 89 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 20 publications and over 250 citings.
Office
136 Mountain View Boulevard
Basking Ridge, NJ 07920
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Chief Residency, Internal Medicine, 2016 - 2017- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2013 - 2016
Northeast Ohio Medical UniversityClass of 2013
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 2016 - 2025
PA State Medical License 2022 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma Start of enrollment: 2022 Jan 27
Roles: Contact, Principal Investigator
- Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Start of enrollment: 2022 Apr 22
Roles: Contact
Publications & Presentations
PubMed
- A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.Angela K Green, Qin Zhou, Alexia Iasonos, William A Zammarrelli, Britta Weigelt
Clinical Cancer Research. 2024-11-19 - 3 citationsNivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.Claire F Friedman, Beryl L Manning-Geist, Qin Zhou, Tara Soumerai, Aliya Holland
Nature Medicine. 2024-05-01 - A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).Melissa Lumish, M Herman Chui, Qin Zhou, Alexia Iasonos, Debra Sarasohn
Gynecologic Oncology. 2024-03-01
Press Mentions
Gateway for Cancer Research Announces Recipient of 4th Annual Young Investigators AwardJune 11th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
